As mentioned last week, here is the flow-diagram for determining whether or not the FDA considers a drug to be "commercially available".
Recall from last week's Newsletter, the interpretation of the statement "regularly or in inordinate amounts":
The FDA interprets this to mean that a drug product that is essentially a copy of a commercially available drug product cannot be compounded regularly (i.e., it cannot be compounded at regular times or intervals, usually, or very often. Please review last week's newsletter for more details.
The FDA does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions for the relevant compounded drug product in a calendar month.
Please obtain a complete copy of this Guidance at URL below and check all of this out.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM510154.pdf
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|